LY3415244

This TIM-3 and PD-L1 bispecific format was associated with unexpected immunogenicity targeting both arms of the bispecific antibody, resulting in early study termination. Epitope specificity analysis revealed an initial response towards the TIM-3 arm and presence of pre‑existing ADAs to the bispecific molecule in the general population. This experience emphasizes the importance of thorough analyses for pre‑existing ADAs as part of immunogenicity risk assessment of novel antibodies.